Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$3.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help investors gauge financial health.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and fund future projects.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. Operating in the health care sector, it aims to improve patient outcomes through innovative drug development, which is crucial as the demand for effective cancer therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1 2026, Tango reported an EPS of -$0.32, matching analyst expectations closely. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Tango's upcoming earnings report, especially given its recent performance. However, uncertainty remains due to the lack of specific guidance from management.

Bull Case

If Tango can report better-than-expected EPS and show signs of revenue growth, it could lead to a significant rally in the stock price, similar to past positive surprises.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

Investors will closely watch this number to determine if the company is on track to improve its financial performance.

What are the revenue expectations for the upcoming quarter?

Revenue figures will be critical in assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Tango's potential for a surprise in EPS due to recent advancements in their pipeline that have not been fully factored into forecasts.

Supporting Evidence

The company's recent stock performance suggests growing investor confidence despite lack of guidance.

Options pricing indicates lower expected volatility compared to historical averages, which may not reflect the company's potential for a positive surprise.

Key Risk

If the EPS comes in better than -$0.30, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reflect the company's ability to navigate a competitive biotech landscape.

Bull Confirmed If

Reporting an EPS above -$0.30 would indicate stronger financial health and investor confidence.

Bear Confirmed If

An EPS below -$0.35 could signal ongoing challenges and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an expected move of about 8.57%, suggesting that traders anticipate some volatility around the earnings announcement.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests a potential stock increase of around 0.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 5.68%, reflecting investor disappointment and concerns over future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines.
2Insights on partnerships or collaborations that could enhance growth.
3Details on market demand for existing products.
4Management's outlook on future revenue streams.
5Responses to competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help investors gauge financial health.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and fund future projects.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1 2026, Tango reported an EPS of -$0.32, matching analyst expectations closely. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Tango can report better-than-expected EPS and show signs of revenue growth, it could lead to a significant rally in the stock price, similar to past positive surprises.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

Investors will closely watch this number to determine if the company is on track to improve its financial performance.

What are the revenue expectations for the upcoming quarter?

Revenue figures will be critical in assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Tango's potential for a surprise in EPS due to recent advancements in their pipeline that have not been fully factored into forecasts.

Supporting Evidence

The company's recent stock performance suggests growing investor confidence despite lack of guidance.

Options pricing indicates lower expected volatility compared to historical averages, which may not reflect the company's potential for a positive surprise.

Key Risk

If the EPS comes in better than -$0.30, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will reflect the company's ability to navigate a competitive biotech landscape.

Bull Confirmed If

Reporting an EPS above -$0.30 would indicate stronger financial health and investor confidence.

Bear Confirmed If

An EPS below -$0.35 could signal ongoing challenges and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an expected move of about 8.57%, suggesting that traders anticipate some volatility around the earnings announcement.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests a potential stock increase of around 0.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 5.68%, reflecting investor disappointment and concerns over future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines.
2Insights on partnerships or collaborations that could enhance growth.
3Details on market demand for existing products.
4Management's outlook on future revenue streams.
5Responses to competitive pressures in the biotechnology sector.